Ultragenyx Pharmaceutical’s (RARE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $95.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company boosted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. JPMorgan Chase & Co. lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Finally, TD Cowen raised their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $88.46.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $43.82 on Tuesday. The stock has a market capitalization of $4.05 billion, a P/E ratio of -6.77 and a beta of 0.56. The company’s 50-day simple moving average is $48.74 and its 200-day simple moving average is $49.35. Ultragenyx Pharmaceutical has a fifty-two week low of $37.02 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. During the same period last year, the business posted ($2.23) earnings per share. The firm’s revenue was up 42.3% compared to the same quarter last year. On average, research analysts forecast that Ultragenyx Pharmaceutical will post -6.2 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emil D. Kakkis sold 8,273 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the sale, the chief executive officer now owns 2,195,712 shares in the company, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the company. True Wealth Design LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth approximately $43,000. nVerses Capital LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $33,000. UMB Bank n.a. grew its stake in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 352 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $83,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.